Non Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Conditions
Keywords
NAFLD, NASH, GLP-1
Brief summary
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.
Detailed description
Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge
Interventions
OTHEROral glucose tolerance test
Oral intake of 75 g glucose after overnight fast
Sponsors
University Hospital, Basel, Switzerland
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Biopsy proven NAFLD or NASH
Exclusion criteria
* additional concomitants liver disease * T2DM * alcohol consumption \>40g/d for male subjects and \>20g/d for female subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucagon-like Peptide 1 (GLP-1) secretion in response to oGTT | 0, 15, 30, 60, 90, 120 min. after glucose administration | The difference in GLP-1 secretion in response to oGTT as assessed by area under the curve (AUC) and peak plasma concentration (cmax) in patients with NAFLD compared to healthy controls. |
Secondary
| Measure | Time frame |
|---|---|
| Insulin secretion and glucose curves in response to oGTT | 0, 15, 30, 60, 90, 120 min. after glucose administration |
Countries
Switzerland
Outcome results
None listed